{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:31:22Z","timestamp":1792809082287,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11523-023-01002-3","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:02:53Z","timestamp":1697698973000},"page":"973-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ivosidenib: A Review in Advanced Cholangiocarcinoma"],"prefix":"10.1007","volume":"18","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"issue":"2","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"key":"1002_CR2","first-page":"557","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"1002_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/17474124.2021.1991313","volume":"15","author":"M Rimini","year":"2021","unstructured":"Rimini M, Puzzoni M, Pedica F, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367\u201383.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/cancers14081950","volume":"14","author":"Y-P Lee","year":"2022","unstructured":"Lee Y-P, Oh SY, Kim KM, et al. Modified FOLFIRINOX as a second-line treatment for patients with gemcitabine-failed advanced biliary tract cancer: a prospective multicenter phase II study. Cancers (Basel). 2022;14(8):1950.","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 1","key":"1002_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/liv.14100","volume":"39","author":"J Adeva","year":"2019","unstructured":"Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(Suppl. 1):123\u201342.","journal-title":"Liver Int"},{"issue":"6","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/life12060829","volume":"12","author":"C-Y Cheng","year":"2022","unstructured":"Cheng C-Y, Chen C-P, Wu C-E. Precision medicine in cholangiocarcinoma: past, present and future. Life. 2022;12(6):829.","journal-title":"Life"},{"issue":"4","key":"1002_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","volume":"10","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitratdehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751\u201365.","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"1002_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","volume":"78","author":"G Kendre","year":"2023","unstructured":"Kendre G, Murugesan K, Brummer T, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78(3):614\u201326.","journal-title":"J Hepatol"},{"issue":"15 suppl","key":"1002_CR9","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2021.39.15_suppl.4009","volume":"39","author":"S Makawita","year":"2021","unstructured":"Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study [abstract no. 4009]. J Clin Oncol. 2021;39(15 suppl):4009.","journal-title":"J Clin Oncol."},{"issue":"7274","key":"1002_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739.","journal-title":"Nature"},{"issue":"5","key":"1002_CR11","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/hep.32424","volume":"75","author":"M-J Wu","year":"2022","unstructured":"Wu M-J, Shi L, Merritt J, et al. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022;75(5):1322\u20137.","journal-title":"Hepatology"},{"issue":"3","key":"1002_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","volume":"12","author":"M-J Wu","year":"2022","unstructured":"Wu M-J, Shi L, Dubrot J, et al. Mutant IDH inhibits IFN\u03b3-TET2 sgnaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2022;12(3):812\u201335.","journal-title":"Cancer Discov"},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo G, Spinelli JB, Perez EM, et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. Science. 2022;377:1519\u201329.","journal-title":"Science"},{"issue":"Suppl 2","key":"1002_CR14","first-page":"A576","volume":"10","author":"HD Saatcioglu","year":"2022","unstructured":"Saatcioglu HD, Valle J, Macarulla T, et al. Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial [abstract no. 552]. J Immunother Cancer. 2022;10(Suppl 2):A576\u20137.","journal-title":"J Immunother Cancer"},{"issue":"7516","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature13441","volume":"513","author":"SK Saha","year":"2014","unstructured":"Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110\u20134.","journal-title":"Nature"},{"issue":"4","key":"1002_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"1002_CR17","unstructured":"Les Laboratoires Servier. Tibsovo (ivosidenib): EU prescribing information. 2023. https:\/\/www.ema.europa.eu\/. Accessed 30 Sept 2023."},{"key":"1002_CR18","unstructured":"Servier Pharmaceutical LLC. TIBSOVO (ivosidenib tablets), for oral use. 2022. https:\/\/www.accessdata.fda.gov\/. Accessed 30 Sept 2023."},{"issue":"9","key":"1002_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","volume":"4","author":"MA Lowery","year":"2019","unstructured":"Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol"},{"issue":"16","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2217\/fon-2020-1274","volume":"17","author":"E Aguado-Fraile","year":"2021","unstructured":"Aguado-Fraile E, Tassinari A, Ishii Y, et al. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol. 2021;17(16):2057\u201374.","journal-title":"Future Oncol"},{"key":"1002_CR22","unstructured":"European Medicines Agency. Tibsovo assessment report. 2023. https:\/\/www.ema.europa.eu\/. Accessed 30 Sept 2023."},{"issue":"8","key":"1002_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-019-02673-6","volume":"75","author":"D Dai","year":"2019","unstructured":"Dai D, Yang H, Nabhan S, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019;75(8):1099\u2013108.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1002_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00280-019-03793-7","volume":"83","author":"C Prakash","year":"2019","unstructured":"Prakash C, Fan B, Altaf S, et al. Pharmacokinetics, absorption, metabolism, and excretion of [14C] ivosidenib (AG-120) in healthy male subjects. Cancer Chemother Pharmacol. 2019;83(5):837\u201348.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1002_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cpdd.821","volume":"10","author":"B Fan","year":"2021","unstructured":"Fan B, Dai D, Cohen M, et al. Effect of mild and moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of a single dose of oral ivosidenib in otherwise healthy participants. Clin Pharmacol Drug Dev. 2021;10(1):99\u2013109.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"1002_CR26","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377.","journal-title":"JAMA Oncol"},{"issue":"3 Suppl.","key":"1002_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2021.39.3_suppl.266","volume":"39","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation [abstract no. 266 plus presentation #GI21]. J Clin Oncol. 2021;39(3 Suppl.):266.","journal-title":"J Clin Oncol."},{"issue":"4 Suppl.","key":"1002_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/JCO.2022.40.4_suppl.388","volume":"40","author":"CX Chamberlain","year":"2022","unstructured":"Chamberlain CX, Hua Z, Gliser C, et al. Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study [abstract no 388 plus poster]. J Clin Oncol. 2022;40(4 Suppl.):388.","journal-title":"J Clin Oncol"},{"key":"1002_CR29","unstructured":"Abou-Alfa GK, Burris S, Adeva J, et al. Characterization of IDH-1 mutant cholangiocarcinoma patients who received ivosidenib treatment longer than a year [poster]. In: 10th Annual cholangiocarcinoma foundation conference, 2023."},{"key":"1002_CR30","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Biliary Tract Cancers Version 2.2023\u2014May 10, 2023. https:\/\/www.nccn.org\/. Accessed 30 Sept 2023."},{"issue":"5","key":"1002_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11523-022-00917-7","volume":"17","author":"M Rimini","year":"2022","unstructured":"Rimini M, Burgio V, Antonuzzo L, et al. Real-world data on ivosidenib in patients with previously treated isocitrate dehydrogenase 1-mutated intrahepatic cholangiocarcinomas: an early exploratory analysis. Target Oncol. 2022;17(5):591\u20136.","journal-title":"Target Oncol"},{"issue":"1","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","volume":"13","author":"R Reinbold","year":"2022","unstructured":"Reinbold R, Hvinden IC, Rabe P, et al. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun. 2022;13(1):4785.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1007\/s11523-024-01106-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01002-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:06:47Z","timestamp":1729620407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01002-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01002-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-024-01106-4","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"12 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-024-01106-4","URL":"https:\/\/doi.org\/10.1007\/s11523-024-01106-4","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}